Piper is reputable and they say MNKD will be taken out!!!! They say OVERWEIGHT....OPC11
Piper Jaffray expects MannKind’s formal partnership process to attract multiple pharma companies, but the firm does not expect a deal to get done before Afrezza’s Food and Drug Administration approval, which it expects in second quarter of next year. However, Piper continues to see MannKind as a takeout story, eventually being acquired by its commercial partner. The firm keeps an Overweight rating on the stock.
the same analysts everyone was crucifying for their awful research? The same researches that completely missed the economic downturn? The same analysts asking the dumbest questions in yesterday's calls? The same analysts that are also issuing downgrades? You're a moron.
If they said it, it must be true. Now I know why I had you on ignore. You're an idiot!